Genmab Logo

Genmab

Creates and develops antibody therapeutics for the treatment of cancer and serious diseases.

GMAB | CO

Overview

Corporate Details

ISIN(s):
DK0010272202 (+2 more)
LEI:
529900MTJPDPE4MHJ122
Country:
Denmark
Address:
Carl Jacobsens Vej 30, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genmab is an international biotechnology company focused on creating and developing differentiated antibody therapeutics for the treatment of cancer and other serious diseases. The company leverages its proprietary antibody science and pioneering technology platforms to innovate next-generation treatments. Genmab's core activities involve the discovery, development, and commercialization of antibody-based products, often in collaboration with strategic partners. Its purpose is to improve the lives of patients by harnessing the power of antibodies to transform medical care.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-29 07:08
M&A Activity
English 25.9 KB
2025-09-29 07:08
M&A Activity
English 234.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 175.3 KB
2025-09-23 15:18
Major Shareholding Notification
English 7.2 KB
2025-09-23 15:18
Major Shareholding Notification
English 2.9 MB
2025-09-09 20:57
Director's Dealing
English 7.1 KB
2025-09-09 20:57
Director's Dealing
English 202.5 KB
2025-09-09 20:54
Share Issue/Capital Change
English 8.2 KB
2025-09-09 20:54
Share Issue/Capital Change
English 175.5 KB
2025-08-12 20:36
Share Issue/Capital Change
English 175.2 KB
2025-08-12 20:36
Share Issue/Capital Change
English 7.8 KB
2025-08-07 17:08
Earnings Release
English 17.2 KB
2025-08-07 17:08
Earnings Release
English 741.7 KB
2025-08-07 16:30
Regulatory News Service
English 207.6 KB
2025-08-07 16:30
Legal Proceedings Report
English 21.0 KB

Automate Your Workflow. Get a real-time feed of all Genmab filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Genmab via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Astena Holdings Co., Ltd. Logo
Develops and sells chemicals, pharma, and ingredients for food, cosmetic, and industrial use.
Japan 8095
AstraZeneca PLC Logo
Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.
United Kingdom AZN
Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea 355690
Bachem Holding AG Logo
A CDMO developing and manufacturing peptides and oligonucleotides for pharma and biotech.
Switzerland BANB
Basilea Pharmaceutica AG Logo
Develops & commercializes anti-infectives for severe bacterial & fungal infections.
Switzerland BSLN
Bavarian Nordic Logo
A biotech firm developing and manufacturing life-saving vaccines for travel and public health.
Denmark BAVA
Bayer AG Logo
A life science firm providing pharmaceuticals, consumer health, and crop science solutions.
Germany BAY
Benchmark Holdings Plc Logo
Aquaculture biotech providing nutrition and health solutions for sustainable farming.
United Kingdom BMK
BIFIDO. Co. Ltd Logo
Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.
South Korea 238200
BioArctic Logo
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
Sweden BIOA

Talk to a Data Expert

Have a question? We'll get back to you promptly.